陳曉光

1978.4-1982.7 佳木斯醫學院醫療系醫學專業學士

1985.8-1988.7 黑龍江中醫學院基礎藥理學專業碩士

1992.8-1994.12 中國醫學科學院/北京協和醫學院藥物研究所博士

1982.08-1985.07 佳木斯醫學院基礎部藥理學教研室助教

1988.08-1992.07 佳木斯醫學院基礎部藥理學教研室講師

1995.01-1996.02 中國醫學科學院/北京協和醫學院藥物研究所助研

1996.03-1996.11 日本大阪市立大學醫學部第二生化學教室客員助教授

1996.12-1997.04 中國醫學科學院/北京協和醫學院藥物研究所副研究員

1997.05-1997.08 瑞士Vaudois州立大學附屬醫院癌研究中心訪問學者

1997.09-1999.09 中國醫學科學院/北京協和醫學院藥物研究所副研究員

1999.10-2000.11 中國醫學科學院/北京協和醫學院藥物研究所研究員

2000.12-2001.08 美國亨利福特醫學中心福特醫院神經科學訪問學者

2001.09～中國醫學科學院/北京協和醫學院藥物研究所研究員

主要從事抗腫瘤藥物的分子藥理學研究及新藥創制與開發，免疫調節劑的研究與開發，主要研究領域為抗腫瘤藥物研究新靶點- MEKK1、PARP1/2、PIN1、HIF-1、HSP90、IDO等抑制劑，PI3K、STAT、Hedgehog等信號通路抑制劑以及與免疫調節密切相關的S1P1受體激動劑和TGF-b抑制劑等方面的研究。主持的1個1.1類新藥已完成I期臨牀研究，正待開展II期臨牀研究，尚有2個1.1類新藥正在進行臨牀前研究。在國內外學術刊物上已發表學術論文100餘篇；申請國內、國際化學發明專利30項，獲得授權專利16項；承擔或完成國家級項目20餘項，其中包括"973"子課題、"863"、國家科技部腫瘤藥效學"技術平台"、多項國家自然科學基金以及國家“十一五”“十二五”新藥重大專項等。主要學術任職：中國抗癌協會抗癌藥物專業委員會委員、中國藥理學會分子與生化藥理專業委員會副主任委員、中國藥學會抗腫瘤藥物專業委員會副主任委員、中國藥學會海洋藥物專業委員會委員、北京藥學會應用藥理專業委員會主任委員，國家科技部重大新藥創制專項“十一五”“十二五”評審專家，CFDA新藥評審專家庫成員，CFDA保健品評審專家，北京生物技術和新醫藥產業促進中心新藥項目評審專家。中國醫學科學院/北京協和醫學院學位評定委員會委員、學術委員會委員，中國醫學科學院藥物研究所學位評定分委會委員，中國醫學科學院藥物研究所學術委員會委員。中華腫瘤學雜誌等編委。2004年被國家人事部等七部委授予首批新世紀百千萬人才工程國家級人選；2005年獲得國家政府特殊津貼。 ^[1] 

1.Li Yan, Tang Ke, Li Chao, NiuFei, Zhou Wanqi, Yang Hanze, Feng Zhiqiang, Chen Xiaoguang. The molecular mechanisms of a novel multi-kinase inhibitor ZLJ33 in suppressing pancreatic cancer growth. Cancer Letter. 2015 Jan 28;392-403.

2.NiuFei, Li Yan, Lai Fangfang, Ni Lin, Ji Ming, Jin Jing, Yang Hanze, Wang Chao, Zhang Dongming, Chen Xiaoguang. LB-1 exerts antitumor activity in pancreatic cancer by inhibiting HIF-1α and Stat3 signaling. J Cell Physiol. 2015 Feb 5. doi: 10.1002/jcp.24949

3.Jing Jin, Jinping Hu, Wanqi Zhou, Xiaojian Wang, Qiong Xiao, Nina Xue, Dali Yin, Xiaoguang Chen. Development of a selective S1P1 receptor agonist, Syl930, as a potential therapeutic agent for autoimmune encephalitis. Biochemical Pharmacology. 2014;90:50-61.

4.Xue nina, Jin Jing, Liu Di, Zhang Sen, Yu xiaoming, Xiaoguang Chen. Antiproliferative effect of HSP90 inhibitor Y306zh against pancreatic cancer is mediated by interruption of AKT and MAPK signaling pathways. Curr Cancer Drug Targets. 2014;14(7):671-83.

5.Wang tianen, Wang yongkang, Jin Jing, Xu bailing, Chen xiaoguang. A novel derivative of quinazoline, WYK431 induces G2/M phase arrest and apoptosis in human gastric cancer BGC823 cells through the PI3K/Akt pathway. International Journal of Oncology.2014;45: 771-781.

6.Ke Tang, Can Luo, Yan Li, Chenshu Lu, Wanqi Zhou, Haihong Huang*, Xiaoguang Chen*. The study of a novel Sorafenib derivative HLC-080 as an antitumor agent. PLOS ONE. 2014;9(7),e101889.

7.Liwei Lang, Xiaoyu Liu, Yan Li, Qing Zhou, Ping Xie, Chunhong Yan*, Xiaoguang Chen*. A Synthetic Manassantin A Derivative Inhibits Hypoxia-Inducible Factor 1 and Tumor Growth. PLOS ONE 2014;9(6)e99584.

8.Tian Yulin1, Jin Jing1, Wang Xiaojian, Hu jinping, Xiao Qiong, Zhou Wanqi, Chen Xiaoguang, Yin Dali. Discovery of oxazole and triazole derivatives as potent and selective S1P(1) agonists through pharmacophore-guided design. Eur J Med Chem. 2014 Oct 6;85:1-15.

9.Mei Mei, Dan Xie, Yi Zhang, Jing Jin, Feng You, Yan Li, Jungui Dai, Xiaoguang Chen. A New 2a,5a,10b,14b-tetraacetoxy-4(20),11-taxadiene(SIA) Derivative Overcomes Paclitaxel Resistance by Inhibiting MAPK Signaling and Increasing Paclitaxel Accumulation in Breast Cancer Cells. PLOS ONE. 2014;9 (8), e104317.

10.LU Chen-shu, TANG Ke, LI Yan, JIN Bo, YIN Da-li, MA Chen, CHEN Xiaoguang*, HUANG Hai-hong*. Synthesis and in vitro antitumor activities of novel benzyl urea analogues of sorafenib. ActaPharmaceuticaSinica, 48(5), 709-717, 2013

11.Sen Zhang, Hongqi Xin, Yan Li, Dongming Zhang, Jing Shi, Jingzhi Yang, Xiaoguang Chen*. Skimmin,aCoumarin from Hydrangea paniculata,Slows down the Progression of Membranous Glomerulonephritis by Anti-Inflammatory Effects and Inhibiting Immune Complex Deposition。Evidence-Based Complementary and Alternative Medicine. :ID 819296, 2013

12.Chunwan Lu, Di Liu, Jing Jin, HemantkumarDeokar, Yi Zhang, John Buolamwini, Xiaoming Yu, Chunhong Yan, Xiaoguang Chen*. Inhibition of gastric tumor growth by a novel Hsp90 inhibitor. Biochemical Pharmacology, 85:1246-1256,2013

13.Jing Jin, Yi Zhang, Yan Li, Haijing Zhang, Hongyan Li, Xia Yuan, Xiangyan Li, Wanqi Zhou, Bailing Xu, Chongjing Zhang, Zhihui Zhang, Lina Zhu, Xiaoguang Chen*.RNA-interference-mediated downregulation of Pin1 suppresses tumorigenicity of malignant melanoma A375 cells.Neoplasma, 60(1):92-100, 2013

14.Jie Zhou1, Jing Jin1, Yi Zhang, Yuwen Yin, Xiaoguang Chen, Bailing Xu. Synthesis and antiproliferative evaluation of novel benzoimidazolecontainedoxazole-bridged analogs of combretastatin A-4.European Journal of Medicinal Chemistry. 68:222-232, 2013

15.Zhang Sen, Li Yan, Li Hongyan, Zheng Xuguang, Chen Xiaoguang*. Renal.protective effect of nicousamide on hypertensive nephropathy in spontaneously hypertensive rats. Biomedical Reports. 1:34-40, 2013

16.Zhang Sen, Li Hongyan, Li Yan, Zhang Furong, Liu Yue, Chen Xiaoguang*. Nicousamide normalizes renovascular hypertension in two-kidney one-clip hypertensive rats. Biomedical Reports. 1:89-92, 2013

17.Zhang Sen, Yang Jingzhi, Li Hongyan, Li Yan, Liu Yue, Zhang Dongming, Zhang Furong, Zhou Wanqi, Chen Xiaoguang*.Skimmin, a coumarin, suppresses the streptozotocin-induced diabetic nephropathy in wistar rats.European Journal of Pharmacology.692:78-83, 2012

18.Li Yan, Zhou Wanqi, Lang Liwei, Jin Jing, Tang Ke, Li Chao, Bin Tena T, Chen Xiaoguang*.The effect of Aurora kinases on cell proliferation,cell cycle regulation and metastasis in renal cell carcinoma. International Journal of Oncology. 41(6) , 41（6）：2139-49, 2012

19.Liu Chang1, Jin Jing1, Chen Liang, Zhou Jie, Chen Xiaoguang, Fu Decai, Song Hongrui, Xu Bailing.Synthesis and biological evaluation of novel human Pin1 inhibitors with benzophenone skeleton. Bioorganic & Medicinal Chemistry. 20:2992-2999, 2012

20.Qing Zhou, Yan Li, Jing Jin, Liwei Lang, Zhixiang Zhu, Weishuo Fang, Xiaoguang Chen*.Lx2-32c, a novel taxane derivative, exerts anti-resistance activity by initiating intrinsic apoptosis pathway in vitro and inhibits the growth of resistant tumor in vivo. Biol. Pharm. Bull. 35(12), 2170-2179, 2012

21.Chaoqing Huang, Xiaoguang Chen, BaolinGuo, Wenhua Huang, Ting Shen, Xinguang Sun, Peigen Xiao and Qing Zhou. Induction of apoptosis by Icariside II through extrinsic and intrinsic signaling pathways in human breast cancer MCF-7 cells.Biosci. Biotechnol. Biochem. 76(7), 1322-1328, 2012

22.Yongkang Wang1, Jing Jin1, Lina Zhu, Yi Zhang, Xiaoguang Chen, Xinqin Gao, Bailing XuSynthesis and antitumor activity of novel 2-(1-substitutedpiperidin-4-ylamino) quinazolines as antitumor agents. Acta Pharmaceutica Sinica. 47(9):1164-1178, 2012

23.Hongyan Li, Yi Zhang, Hongbo Wang, Xuguang Zheng, Xiaoguang Chen*. Nicousamide blocks the effects of advanced glycation end products on renal cells. European J. of Pharmacology, 674:455-459, 2012

24.Zhenjia Liu, HainingLv, Hongyan Li, Yi Zhang, Haijing Zhang, Fuqin Su, Song Xu, Yong Li, Yikang Si, Shishan Yu, Xiaoguang Chen*. (+)-13a-(S)-deoxytylophorinine, a new phenanthroindolizidine anticancer alkaloid, sequence-specifically lnteracts with DNA in an intercalating manner. Chemotherapy, 57:310-320, 2011

25.Zhenjia Liu, HainingLv, Hongyan Li, Yi Zhang, Haijing Zhang, Fuqin Su, Yikang Si, Shishan Yu, Xiaoguang Chen*.Anticancer effect and neurotoxicity of S-(+)-deoxytylophorinidine, a new phenanthroindolizidine alkaloid that interacts with nucleic acids. Journal of Asian Natural Products Research. 5(13),400-408, 2011

26.Xiangyan Li, Yan Li, Yi Zhang, Ke Wang, Xia Yuan, Jing Jin, Yan Zhang, Zhanzhu Liu, Xiaoguang Chen*. A novel bisindolymaleimide derivative (WK234) in hibits proliferation and induces apoptosis through the protein kinase C b pathway, in chronic myelogenous leukemia K562 cells. Leukemia & Lymphoma. 52(7): 1312-20., 2011

27.Xia Yuan, Yi Zhang, Haijing Zhang, Jing Jin, Xiangyan Li, He Liu, Zhiqiang Feng, Xiaoguang Chen*. Activity of the potent dual Abl/Src tyrosine kinase inhibitor FB2 against Bcr-Abl positive cell lines in vitro and in vivo. Leukemia Research.; 35(2):237-42, 2011

28.Li Yan, tang Ke, Zhang Haijing, Zhang Yi, Zhou Wanqi, Chen Xiaoguang*. Function of Aurora kinase A in Taxol-resistant breast cancer and its correlation with P-gp.Molecular Medicine Reports.4:739-746, 2011

29.Jing Li, Yang Meng, Yue Liu, Zhiqiang Feng, Xiaoguang Chen*. F84, a quinazoline derivative, exhibits high potent antitumor activity against human gynecologic malignancies. Investigational New Drugs, 28(2): : 132-138, 2010

30. Zhang Yi; Li Hongyan; Wang Hongbo; Su Fuqin; Qu Runjiang; Yin Dali; Dai Jungui; Li Yan; Chen Xiaoguang*. Syl611, a novel semisynthetic taxane derivative, reverses multidrug resistance by p-glycoprotein inhibition and facilitating inward transmembrane action. Cancer Chemotherapy and Pharmacology. 66:851–859, 2010

31.Li Hongyan, Zheng Xu guang, Wang Hongbo, Zhang Yi, Xin Hongqi and Chen Xiaoguang*. XLF-III-43, a novel coumarin-aspirin compound, prevents diabetic nephropathy in rats via inhibiting advanced glycation end products. European J. Pharmacology; 627:340-347, 2010 ^[1]